Under the Paperwork Reduction Act of 1995, no persons are may	Tours and Tour	513 622 3388 P. 82/88 PTO/SB/17 (10/00) Approved use through 10/31/2002, OMB 0651-0032 demark Office: U.S. DEPARTMENT OF COMMERCE formation unless it displays a valid OMB control number				
FEE TRANSMITTAL	Complete if Known					
f r FY 2001	Application Number	09/607,602				
Parent fees are subject to annual revision.	Filing Date	June 30, 2000				
	First Named Inventor	Matthew Joseph Doyle				
	Examiner Name	A. DeCloux				
	Group/Art Unit	1644				
TOTAL AMOUNT OF PAYMENT (\$)0.00	Attorney Dacket No	8141				

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)								
					3 AF	OITION	C FEE	5		
(X) Th	e Com	mission	er is hol	eby authorized to charge indicated	Large	Entity	Small	Entity		
fe	es and	credit at	ny over	payments to:	Fee	Fee	Fee	Foo		Fee Paid
posit Acc	ount Nu	imper ;	16-2480		Code	(3)	Code	(5)		G Car
posit Acc	ount Na	ime		octor & Gambie Company	105	130	205	65	Surcharge - late filling fee or own Surcharge - late provisional filling	Ö
		udditional	Fee	Applicant claims ameli entity	127	50	227	25	ges or cover speet	
Requ	tred Und	ler		status, See 37 CFR §127	139	130	139	130	Non-English apacification	0
37 C.	F.R. 551	,16 and	1.17				147	2.520	For filing a request for ex perts	ā
[] Paym	ent En	dosed:			147	2,520	147	2,520	maximization	•
D					112	920"	112	920*	Requesting publication of SIR prior	0
[] Check	пс	redit Ca	ird N	Money Order [] Other	1 112	#2.U	114	JLU	to Examiner's action	-
U 01140	<u> </u>				1113	1.840"	113	1.840*	Requesting publication of SIR after	Ū
		EFF	CAL	CULATION	1 ''3	1,040		.,	Examiner's action	
			- VAL		1115	110	215	55	Extension for reply within 1st month	0
BASIC	ILING	FEE			118	390	216	195	Extension for reply within 2" month	Ō
rge Entity			_	a Description Fee Paid	1117	890	217	445	Extension for reply within 3" month	Ċ
ee Fae	Fee	Fee	Fe	e Description Fee Paid	1118	1,390	218	695	Extension for reply within 4th month	0
de (5)	Code			no.au:4	128	1.890	228	945	Extension for reply within 5th month	0
01 710	201	355		ity fling fee [] eign filing fee []	119	310	219	155	Notice of Appeal	O
08 320	206			eign filing fee [] ent filing fee []	120	310	220	155	Filing a brief in support of an appeal	0
07 490	207			ing nang ree () issue filing fee ()	121	270	221	135	Request for oral hearing	0
08 710	208			ovisional filing fee	138	1.510	138	1,510	Publica to institute a public use proceeding	a D
14 150	214	/9		OTAL (1) (\$)[]	140	110	240	55	Petition to revive - unavoidable	0
	50 A 48 6		3001	CIAC(I) (ON	141	1.240	241	620	Patition to revive - unintentional	B
EXTRA	CLAIM	FEE2		Fee From	142	1.240	242	620	Utility leave fee (or release)	0
				Extra Claims Below Fee Paid	143	440	243	220	Design leave fee	0
	_		1 - 20"		144	600	244	300	Plant Issue fee	0
otal Claim Idepender] - 20] - 3"		122	130	122	130	Petitions to the Commissioner	0
luitiple De			, .	- "	123	50	123	50	Patitions related to previolent application	
or army	na busing	er Griege de	id. If an	sater, For Reissues, see below	126	240	126	240	Submission of IDS	Õ
or marries	- Pierr	, pa			581	40	581	40	Recording each patent assignment	
Larme	Entity	Small	Entity		1		•••	355	per property (times number of propertie Filing a submission after final reject	as) kon 1ì
Fee	Fee	Fee	Fee	Fee Description	146	710	248	333	(37 CFR § 1,129(a))	U
Code	(\$)	Code	(5)	#I-I to success -1 30	149	710	248	355	For each additional invention to be	G
103	18	203	9	Claims in excess of 20 Independent claims in excess of 3	179	, 10	4-40		examined (37 CFR §1.128(b)	•
102	80	202	40	Multiple dependent claim, if not	179	710	279	355	Request for Continued Examination (RCI	
104	270	204	135	writible debandant craw, a nor	169	710			Request for expedited examination	
400	80	209	40	**Reissue independent claims	'''				of a dealgn application	
109	80	208	40	over original patent	Othe	r fee (sp	ecify) _		<u></u>	0
110	18	210	9	Reissue dalma in excess of 20 and over original patent		r fee (sp				0
		_	SUB.	TOTAL (2) (\$)[]	- R	educed b	y Basi	Filing F	ee Paid SUBTOTAL(3) (5	5) 0

SUBMITTED BY	Complete	Complete (if applicable)			
Name (Print/Type)	Emelyn L. Hiland	Registration No. (AtomsylAgent)	41,501	Telephone	(613) 622-3236
	Emlin L. Wiland				

Signature

WADDRE: Internation on the limit key become public. Graff Card Internation should not be included on this form. Provide street and information and PT-0004.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. These will very deported up point the included of the individual cases. Any comments on the amount of time you are required to complete this form should be sent to the Christ Internation Offices, Peterst and Trademark Office, Witerlington, D.C. 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, D.C. 20231.

P&G HC PATENT DIV.

513 622 3300 P.03/08

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Case Docket No. 8141

In the Application of

Inventor(s):

MATTHEW JOSEPH DOYLE, ET AL.

Serial No.:

09/607,602

Group Art Unit: 1644

Date Filed:

June 30, 2000

Examiner: A. DeCloux

Title: PROMOTING WHOLE BODY HEALTH

RESPONSE UNDER § 1.111

THE COMMISSIONER FOR PATENTS Washington D.C. 20231

Dear Sir:

In response to the Office Action dated September 27, 2001 and having a period for response of one month thereafter, please consider the amendments and remarks herein. No response fee is known to be due as this response is being submitted within the prescribed period.

<u>AMENDMENT</u>

In the Claims

Please amend Claims 1-7 to read as follows.

1. A topical oral composition for treating and preventing oral cavity diseases in human and other animal subjects and thereby promoting whole body health in said human and other animal subjects, said composition comprising of safe and effective amount of a host-response modulating agent, and a pharmaceutically acceptable oral carrier, wherein said host-response modulating agent is selected from a H2-antagonist; anti-inflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins and nutrients key to maintenance of a host response balance, inhibitor of activation of NF-kB, and mixtures thereof.

2. A method for treating and preventing oral cavity diseases in human and other animal subjects and thereby promoting whole body health in said human and other animal subjects,